FHU CARE aims at bringing together clinicians and scientists involved in Autoimmune Diseases, Inflammatory Diseases and Cancer to favor the emergence of new paradigms :

Pathophysiology of Cancer and of Autoimmune Diseases (AID) / Inflammatory Diseases (ID) may share common or opposite mechanisms.
Treatment of Autoimmunity and treatment of Cancer are inter-related.

Presentation of FHU CARE by Professor Xavier Mariette

Presentation of FHU CARE by Professor Xavier Mariette

FHU CARE WORK PACKAGES

Our community is very rich in experts involved in auto-immunity/inflammation and cancer focused on the following research actions :

All Work Packages All our Experts

Common pathways involved in Autoimmune Diseases, Cancer and Inflammatory Diseases

Adaptive and innate Immunity. The balance between pro vs anti-Inflammatory Immune cells (macrophages, T cells, dendritic cells) is opposed in C vs AID/ID.

Auto-Immunity and Inflammation are risk factors of Cancer

Risk of Cancer in Autoimmune Diseases and Inflammatory Diseases. Risks, implications and evolution, drugs and new perspectives in Cancer Immune surveillance.

Immune-Related Adverse Events (irAEs), in the immunotherapy of Cancer

Management of adverse events, modulation of Autoimmunity, modulating microbiome treatment to cure Cancer.

Teaching the relation between Auto-Immunity and Cancer

Specific training on Autoimmune Diseases, Cancer and Inflammatory Diseases, will be implemented in the University Diplomas.

CLINICAL RESEARCH:
Observational studies
Interventional studies
Clinical trials

Observational studies: They improve the knowledge of the disease and its evolution over time. They are carried out within the framework of the follow-up of the patients in the reference centers.

Interventional studies or clinical trials: They provide scientific evidence of the efficacy and safety of a new drug, a new care device or a new management in the context of an illness. This is the necessary step for a new molecule to become a drug or a new medical device to be marketed.

E-TRAINING BY FHU CARE

Online Courses :
Management of Immuno-Related Complications Cancer Immunotherapy

Learn more about immunotherapy in oncology with 3 modules:

Identify the main molecules and their mechanisms of action
Learn more about the actual and forecoming indications
Identify and manage Immune related adverse events

For more information

Presentation of FHU CARE courses by Professor Olivier Lambotte

[Symposium iTOX 2025] Cancer Immunotherapy Adverse Events

European Alliance of Associations for Rheumatology [EULAR] 2025

[Séminaire] Cancers et Maladies Auto-Immunes : vers une médecine de précision grâce à l’IA

Anti-PD-1 amplifies co-stimulation in melanoma-infiltrating Th1-like Foxp3+ Regulatory T cells to alleviate local immunosuppression TIJC#7

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer #TIJC6

Les Appels à Projets DIM ITAC (Immunothérapie - Auto-immunité – Cancer) sont ouverts ! Date limite : mercredi 26 mars 2025

Neoantigen vaccines: a new era of precision medicine in oncology TIJC#5

Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division (Nat Immunol.) TIJC#4

KICKOFF MEETING 2025

FITC WEBINARS IMMUNOTHERAPY RESEARCH Tumor-Stroma Interface Regulation Of immune response and response to immunotherapy

Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis. #TIJC 3

TIJC#2 : The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer, Nature 2024.

Nouveau Diplôme Universitaire (DU) 2024-2025 : Mathématiques Appliquées au Cancer?

REPLAY !! Transdisciplinary Immunology Journal Club - Watch now and catch up on previous sessions!

Transdisciplinary Immunology Journal Club #1 JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma

Unlocking Immune Diversity: Discover the power of a Disruptive qTCR-seq Platform. #Seqalis

DIM ITAC - Appel à Projets « Equipements » 2023

Congrès RIIP : Rencontres en Immunologie et Immunothérapie Pratiques !

MAIN ACHIEVEMENTS & SIGNIFICANT ACTIONS 2020-2024

INTERNATIONAL MEETING IMPROVING ADOPTIVE CELL THERAPY

Workshop Scientifique Inter-FHUs/IHUs : Recherche et Perspectives

Symposium iTOX mercredi 22 et jeudi 23 mai 2024

Women in Science > REVOIR la vidéo récap !! Santé des femmes et Femmes de santé

Jeunes Talents France Bourses L'OREAL Unesco

Les thérapies cellulaires CAR-T en immunologie et en rhumatologie

ITAC DIM AAP - Projet collaboratif

C2i COLLOQUE INTENSIF D'IMMUNO-RHUMATOLOGIE

ITAC DIM AAP - Manifestation scientifique

Colloque « Régulations épigénétiques et post-transcriptionnelles : de la physiopathologie à l’innovation thérapeutique »

#HighlyCited2023 RESEARCHERS 2023 Université Paris-Saclay, Gustave Roussy > Nombreux en cancérologie et 1 en Autoimmunité !!!

Workshop Women in Science : Santé des Femmes et Femmes de Santé WiS#2byFHUs

Incucyte® - Live-Cell Analysis Systems > équipement de pointe qui révolutionnera nos recherches en immunothérapie, auto-immunité et cancer.

Assemblée Générale FHU CARE 2024

LA FITC PRÉSENTE SES HIGHLIGHTS EN IMMUNO-ONCOLOGIE LORS D’UNE ÉMISSION EN DIRECT

Appel MRSEI de l’ANR pour aider au Montage de Réseaux Scientifiques Européens ou Internationaux - MRSEI 2023

Journée mondiale de lutte contre le sepsis

SPOC MIRACIP Management of immunorelated complication of cancer immunotherapy 100% e-learning

New publication ! Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.

FITC Annual Meeting 12/09/2023

DGOS, AAP 2023 : PHRC-Interrégional, PHRC-N, PHRIP, PREPS, PRME, PHRC-K, PRT-K

ANR Appel à projets générique – 2024

France 2030

Appel à projet Carnot@APHP pour les FHU 2023

The 6th DCBIOL course on Immunity and Cancer Immunotherapy

AAP Thésaurus GIRCI

Un nouveau portail : appelsprojetsrecherche.fr

AG FHU CARE

Symposium iTOX 2023 : 25-26 mai 2023 #FORMATION

all news and events

INRAE

Institut Gustave Roussy

Université Paris Saclay

INSERM

AP-HP

CEA

Fondation Arthritis

Copyright © 2022 FHU CARE - Tous droits réservés | legal | Presse

Création du site Internet scientifique Nice Paris
Agence de communciation scientifique - Paris / Nice